{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:10:14Z","timestamp":1776881414678,"version":"3.51.2"},"reference-count":49,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RAIAD"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n<jats:title>Background and Objective:<\/jats:title>\n<jats:p>Type 1 diabetes mellitus is a complex disease defined by\nthe loss of pancreatic cells, which leads to complete insulin insufficiency. The Diabetes Control\nand Problems Trial defines the aims of Type 1 diabetes therapy as achieving adequate glycaemic\ncontrol, and preventing and avoiding recurrent bouts of hypoglycaemia. Despite ongoing efforts to\nimprove insulin therapy regimens, the actual hormone substitute therapy treats just the symptoms\nof the disease, with no influence on disease pathology or etiopathogenesis. In recent decades, there\nhas been a lot of interest in preventative techniques in high-risk patients, based on the theory that\nif a therapeutic intervention is adopted early in the disease, it can help maintain endogenous cell\nfunction by protecting the remaining cell reservoir from autoimmune attack.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Based on preclinical and clinical data, we have discussed some immunotherapeutic in\nthis meta-analysis. We referred to the preclinical and clinical studies for teplizumab and rituximab\nfrom authentic databases and compiled the data. We used statistical analysis to do a meta-analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>In two immunotherapeutic anti-CD3 antibodies and anti-CD20 antibodies examples, teplizumab\nand rituximab, respectively, shows better efficacy as well as fewer side effects. We have\ndiscussed this drug briefly based on their mechanism of action and meta-analysis, which compare\nclinical efficacy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Immunotherapeutic can be a better option for preventing and protecting type one diabetes.\nSince, the existing literature does not have enough data to support any single drug concluding\nthe same will not be appropriate. Hence further studies are required wherein different drugs\ncan be compared with similar sample sizes for each group of drugs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/2772270817666221122103029","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T04:33:51Z","timestamp":1669178031000},"page":"64-70","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody:\nImmunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes"],"prefix":"10.2174","volume":"17","author":[{"given":"Shivani","family":"Desai","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajakta","family":"Kashalikar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avinash","family":"Sanap","sequence":"additional","affiliation":[{"name":"Regenerative Medicine Lab, Dr. D.Y. Patil Dental College and Hospital, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhura","family":"Shekatkar","sequence":"additional","affiliation":[{"name":"Regenerative Medicine Lab, Dr. D.Y. Patil Dental College and Hospital, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Bhonde","sequence":"additional","affiliation":[{"name":"Director Research, Dr. D.Y.\nPatil Vidyapeeth, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3389\/fimmu.2018.00392","volume":"9","author":"Smith E.L.","year":"2018","unstructured":"Smith E.L.; Peakman M.; Peptide immunotherapy for type 1 diabetes-clinical advances. Front Immunol 2018,9(FEB),392","journal-title":"Front Immunol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","volume":"391","author":"DiMeglio L.A.","year":"2018","unstructured":"DiMeglio L.A.; Evans-Molina C.; Oram R.A.; Type 1 diabetes. Lancet 2018,391(10138),2449-2462","journal-title":"Lancet"},{"key":"ref=3","first-page":"1","author":"Rapini N.","year":"2020","unstructured":"Rapini N.; Schiaffini R.; Immunotherapy strategies for the prevention and treatment of distinct stages of type 1 diabetes: An overview. Int J Mol Sci 2020,1-11","journal-title":"Int J Mol Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"22584","DOI":"10.3390\/ijms160922584","volume":"16","author":"Perri V.","year":"2015","unstructured":"Perri V.; Russo B.; Crin\u00f2 A.; Expression of PD-1 molecule on regulatory T lymphocytes in patients with insulin-dependent diabetes mellitus. Int J Mol Sci 2015,16(9),22584-22605","journal-title":"Int J Mol Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e0210839","DOI":"10.1371\/journal.pone.0210839","volume":"14","author":"Pellegrino M.","year":"2019","unstructured":"Pellegrino M.; Crin\u00f2 A.; Rosado M.M.; Fierabracci A.; Identification and functional characterization of CD8+ T regulatory cells in type 1 diabetes patients. PLoS One 2019,14(1),e0210839","journal-title":"PLoS One"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2006.03244.x","volume":"148","author":"Di Lorenzo T.P.","year":"2007","unstructured":"Di Lorenzo T.P.; Peakman M.; Roep B.O.; Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol 2007,148(1),1-16","journal-title":"Clin Exp Immunol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","volume":"44","author":"Care D.","year":"2021","unstructured":"Care D.; Suppl S.S.; American Diabetes Association 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care 2021,44(Suppl. 1),S15-S33","journal-title":"Diabetes Care"},{"key":"ref=8","author":"Von A.","year":"2009","unstructured":"Von A.; Bench to Clinic Symposia Immunotherapy for the Prevention and Treatment of Type 1 Diabetes Optimizing the path from bench to bedside. 2009"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2337\/dc15-1419","volume":"38","author":"Insel R.A.","year":"2015","unstructured":"Insel R.A.; Dunne J.L.; Atkinson M.A.; Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine society, and the american diabetes association. Diabetes Care 2015,38(10),1964-1974","journal-title":"Diabetes Care"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2018.12.003","volume":"139","author":"Ni Q.","year":"2019","unstructured":"Ni Q.; Pham N.B.; Meng W.S.; Zhu G.; Chen X.; Advances in immunotherapy of type I diabetes. Adv Drug Deliv Rev 2019,139,83-91","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2337\/diacare.28.5.1068","volume":"28","author":"Skyler J.S.","year":"2005","unstructured":"Skyler J.S.; Krischer J.P.; Wolfsdorf J.; Effects of oral insulin in relatives of patients with type 1 diabetes: The diabetes prevention trial--type 1. Diabetes Care 2005,28(5),1068-1076","journal-title":"Diabetes Care"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa012350","volume":"346","author":"England T.N.","year":"2002","unstructured":"England T.N.; Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002,346(22),1685-1691","journal-title":"N Engl J Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2337\/dc07-1308","volume":"31","author":"Brophy S.","year":"2008","unstructured":"Brophy S.; Yderstr\u00e6de K.; Mauricio D.; Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 2008,31(3),439-441","journal-title":"Diabetes Care"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"894","DOI":"10.2337\/diabetes.47.6.894","volume":"47","author":"Tisch R.","year":"1998","unstructured":"Tisch R.; Liblau R.S.; Yang X.D.; Liblau P.; McDevitt H.O.; Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998,47(6),894-899","journal-title":"Diabetes"},{"key":"ref=15","first-page":"516","volume":"10","author":"Hinke S.A.","year":"2008","unstructured":"Hinke S.A.; Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes. Curr Opin Mol Ther 2008,10(5),516-525","journal-title":"Curr Opin Mol Ther"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/pedi.12611","volume":"19","author":"Elding Larsson H.","year":"2018","unstructured":"Elding Larsson H.; Lundgren M.; Jonsdottir B.; Cuthbertson D.; Krischer J.; Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. Pediatr Diabetes 2018,19(3),410-419","journal-title":"Pediatr Diabetes"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1073\/pnas.91.1.123","volume":"91","author":"Chatenoud L.","year":"1994","unstructured":"Chatenoud L.; Thervet E.; Primo J.; Bach J.F.; Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994,91(1),123-127","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","volume":"54","author":"Herold K.C.","year":"2005","unstructured":"Herold K.C.; Gitelman S.E.; Masharani U.; A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005,54(6),1763-1769","journal-title":"Diabetes"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"933","DOI":"10.4049\/jimmunol.168.2.933","volume":"168","author":"von Herrath M.G.","year":"2002","unstructured":"von Herrath M.G.; Coon B.; Wolfe T.; Chatenoud L.; Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J Immunol 2002,168(2),933-941","journal-title":"J Immunol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1056\/NEJMoa043980","volume":"352","author":"Keymeulen B.","year":"2005","unstructured":"Keymeulen B.; Vandemeulebroucke E.; Ziegler A.G.; Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005,352(25),2598-2608","journal-title":"N Engl J Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"Herold K.C.","year":"2019","unstructured":"Herold K.C.; Bundy B.N.; Long S.A.; An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019,381(7),603-613","journal-title":"N Engl J Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.2337\/dc13-0327","volume":"37","author":"Aronson R.","year":"2014","unstructured":"Aronson R.; Gottlieb P.A.; Christiansen J.S.; Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 2014,37(10),2746-2754","journal-title":"Diabetes Care"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1172\/JCI32405","volume":"117","author":"Hu C.","year":"2007","unstructured":"Hu C.; Rodriguez-Pinto D.; Du W.; Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007,117(12),3857-3867","journal-title":"J Clin Invest"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","volume":"361","author":"Becker D.J.","year":"2009","unstructured":"Becker D.J.; Gitelman S.E.; Goland R.; Gottlieb P.A.; Marks J.B.; Mcgee P.F.; Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009,361(22),2143-2152","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/1043-4666(93)90003-N","volume":"5","author":"Mandrup-Poulsen T.","year":"1993","unstructured":"Mandrup-Poulsen T.; Zumsteg U.; Reimers J.; Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic \u03b2-cell destruction in insulin-dependent diabetes mellitus. Cytokine 1993,5(3),185-191","journal-title":"Cytokine"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1055\/s-2007-1001730","volume":"26","author":"Argil\u00e9s J.M.","year":"1994","unstructured":"Argil\u00e9s J.M.; L\u00f3pez-Soriano J.; L\u00f3pez-Soriano F.J.; Cytokines and diabetes: The final step? Involvement of TNF-alpha in both type I and II diabetes mellitus. Horm Metab Res 1994,26(10),447-449","journal-title":"Horm Metab Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1073\/pnas.87.6.2239","volume":"87","author":"Held W.","year":"1990","unstructured":"Held W.; MacDonald H.R.; Weissman I.L.; Hess M.W.; Mueller C.; Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci USA 1990,87(6),2239-2243","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.4049\/jimmunol.141.7.2325","volume":"141","author":"Campbell I.L.","year":"1988","unstructured":"Campbell I.L.; Iscaro A.; Harrison L.C.; IFN-gamma and tumor necrosis factor-alpha. Cytotoxicity to murine islets of Langerhans. J Immunol 1988,141(7),2325-2329","journal-title":"J Immunol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.4049\/jimmunol.139.12.4077","volume":"139","author":"Mandrup-Poulsen T.","year":"1987","unstructured":"Mandrup-Poulsen T.; Bendtzen K.; Dinarello C.A.; Nerup J.; Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. J Immunol 1987,139(12),4077-4082","journal-title":"J Immunol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.18240\/ijo.2019.07.05","volume":"12","author":"Ye Q.","year":"2019","unstructured":"Ye Q.; Lin Y.N.; Xie M.S.; Effects of etanercept on the apoptosis of ganglion cells and expression of Fas, TNF-\u03b1 caspase-8 in the retina of diabetic rats. Int J Ophthalmol 2019,12(7),1083-1088","journal-title":"Int J Ophthalmol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.2337\/dc09-0054","volume":"32","author":"Mastrandrea L.","year":"2009","unstructured":"Mastrandrea L.; Yu J.; Behrens T.; Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009,32(7),1244-1249","journal-title":"Diabetes Care"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/ph14040320","volume":"14","author":"Hsu C.","year":"2021","unstructured":"Hsu C.; Li Y.; Hsu C.; Cheng J.; Lin M.; Cheng K.; Etanercept ameliorates cardiac fibrosis in rats with diet-induced obesity. Pharmaceuticals 2021,14(4),320","journal-title":"Pharmaceuticals"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0168-8227(90)90017-N","volume":"8","author":"Harada M.","year":"1990","unstructured":"Harada M.; Kishimoto Y.; Makino S.; Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. Diabetes Res Clin Pract 1990,8(2),85-89","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.2337\/db21-1142-P","volume":"70","year":"2021","unstructured":"1142-P: Update on BCG Clinical Trial Programs in Patients with Advanced Type 1 Diabetes. Diabetes 2021,70(S1),1142","journal-title":"Diabetes"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"612584","DOI":"10.3389\/fimmu.2020.612584","volume":"11","author":"Moin A.S.M.","year":"2021","unstructured":"Moin A.S.M.; Nandakumar M.; Diane A.; Dehbi M.; Butler A.E.; The role of heat shock Proteins in type 1 diabetes. Front Immunol 2021,11,612584","journal-title":"Front Immunol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/dmrr.691","volume":"23","author":"Huurman V.A.L.","year":"2007","unstructured":"Huurman V.A.L.; Decochez K.; Mathieu C.; Cohen I.R.; Roep B.O.; Therapy with the hsp60 peptide DiaPep277\u2122 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007,23(4),269-275","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.4049\/jimmunol.172.3.1437","volume":"172","author":"Yu X.Z.","year":"2004","unstructured":"Yu X.Z.; Levin S.D.; Madrenas J.; Anasetti C.; Lck is required for activation-induced T cell death after TCR ligation with partial agonists. J Immunol 2004,172(3),1437-1443","journal-title":"J Immunol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2249.1996.tb08307.x","volume":"103","author":"Ben-Amor A.","year":"2007","unstructured":"Ben-Amor A.; Leite-De-Moraes M.C.; Lepault F.; In vitro T cell unresponsiveness following low-dose injection of anti-CD3 MoAb. Clin Exp Immunol 2007,103(3),491-498","journal-title":"Clin Exp Immunol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/imm.12729","volume":"151","author":"Wallberg M.","year":"2017","unstructured":"Wallberg M.; Recino A.; Phillips J.; Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity. Immunology 2017,151(2),248-260","journal-title":"Immunology"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2904-13","DOI":"10.1172\/JCI23961","volume":"115","author":"Bisikirska B.","year":"2005","unstructured":"Bisikirska B.; Colgan J.; Luban J.; Bluestone J.A.; Herold K.C.; TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005,115(10),2904-13","journal-title":"J Clin Invest"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"Available from:","DOI":"10.1007\/s10668-020-01134-w","volume":"23","author":"Li L.","year":"2021","unstructured":"Li L.; Ran T.; Gao D.; Ting Q.; Yue D.B.; Was Mauritius really successful in banning plastic carry bags, after promulgation of the regulation prohibiting plastic bags usage? Environ Develop Sustainab 2021,23(8),Available from:","journal-title":"Environ Develop Sustainab"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.7717\/peerj.31","volume":"1","author":"Small G.W.","year":"2013","unstructured":"Small G.W.; McLeod H.L.; Richards K.L.; Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. PeerJ 2013,1,e31","journal-title":"PeerJ"},{"key":"ref=43","first-page":"13","volume":"2016","author":"Ivanova N.","year":"2016","unstructured":"Ivanova N.; Gugleva V.; Dobreva M.; Pehlivanov I.; Stefanov S.; Andonova V.; We are IntechOpen, the world\u2019s leading publisher of Open Access books built by scientists, for scientists TOP 1%. Intech 2016,2016,13","journal-title":"Intech"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.290.5489.84","volume":"290","author":"Ravetch J.V.","year":"2000","unstructured":"Ravetch J.V.; Lanier L.L.; Immune inhibitory receptors. Science 2000,290(5489),84-89","journal-title":"Science"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"Smith M.R.","year":"2003","unstructured":"Smith M.R.; Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003,22(47),7359-7368","journal-title":"Oncogene"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"Clynes R.A.","year":"2000","unstructured":"Clynes R.A.; Towers T.L.; Presta L.G.; Ravetch J.V.; Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000,6(4),443-446","journal-title":"Nat Med"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar3907","author":"Kalampokis I.","year":"2013","unstructured":"Kalampokis I.; Yoshizaki A.; Tedder T.F.; IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther 2013(Suppl. 1),S1","journal-title":"Arthritis Res Ther"},{"key":"ref=48","first-page":"836","volume":"8","author":"Alas S.","year":"2002","unstructured":"Alas S.; Ng C.P.; Bonavida B.; Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin\u2019s lymphoma. Clin Cancer Res 2002,8(3),836-845","journal-title":"Clin Cancer Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00125-012-2753-4","volume":"56","author":"Herold K.C.","year":"2013","unstructured":"Herold K.C.; Gitelman S.E.; Willi S.M.; Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: A randomised controlled trial. Diabetologia 2013,56(2),391-400","journal-title":"Diabetologia"}],"container-title":["Recent Advances in Inflammation &amp; Allergy Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2772270817666221122103029","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211108\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2772270817666221122103029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T12:19:11Z","timestamp":1693570751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211108\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2772270817666221122103029","relation":{},"ISSN":["2772-2708"],"issn-type":[{"value":"2772-2708","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}